Mack G J, Rees J, Sandblom O, Balczon R, Fritzler M J, Rattner J B
The University of Calgary, Alberta, Canada.
Arthritis Rheum. 1998 Mar;41(3):551-8. doi: 10.1002/1529-0131(199803)41:3<551::AID-ART22>3.0.CO;2-X.
Human autoantibodies reacting with protein components of the microtubule organizing center of the cell, the centrosome, are rare and have not been extensively studied. We therefore investigated the number, type, and frequency of autoantibodies reactive with centrosomal proteins in a cohort of human sera.
To establish the type of autoantibodies found in autoimmune sera reactive with the centrosome, we used a prototype human serum, which was chosen for its intense reactivity with the centrosome throughout the cell cycle, to screen a HeLa complementary DNA (cDNA) (expression) library. Positive cDNA clones were sequenced and classified as encoding either known centrosomal autoantigens, known centrosomal proteins but unknown as human autoantigens, or previously unknown centrosomal antigens. To investigate whether these centrosomal autoantibody classes were characteristic of centrosomal-reactive sera, sera from 21 subjects with centrosomal reactivity by indirect immunofluorescence were characterized by Western blotting for reactivity to recombinant protein from each of the classes of centrosomal antigens. Clinical features were studied by retrospective chart review.
In each of the sera, autoantibodies that recognize a group of centrosomal proteins were identified. This group included known centrosomal autoantigens (pericentrin and pericentriolar material 1 [PCM-1]), the human homolog of a known mouse centrosomal protein, ninein, which was previously unknown as a human autoantigen, and a novel centrosomal protein (Cep250). Autoantibodies to PCM-1 were the least common (8 of 21 subjects; 38%) while those to ninein, Cep250, and pericentrin occurred at roughly equal frequencies (17 subjects [81%], 17 subjects [81%], and 19 subjects [90%], respectively). There was no apparent correlation between serum autoantibody reactivity and the clinical diagnosis.
Each of the autoimmune sera contained autoantibodies that reacted with a group of centrosomal proteins. We found that the centrosomal component ninein, first identified in mice, has a human homolog that is an autoantigen. Also, anticentrosomal sera contained antibodies to previously undetected centrosomal components. One of these novel antigens was identified and was designated Cep250. Thus, a characteristic of sera reactive with the centrosome is that they contain antibodies to a group of centrosomal proteins.
与细胞微管组织中心(即中心体)的蛋白质成分发生反应的人类自身抗体较为罕见,尚未得到广泛研究。因此,我们调查了一组人类血清中与中心体蛋白发生反应的自身抗体的数量、类型和频率。
为确定在与中心体发生反应的自身免疫血清中发现的自身抗体类型,我们使用了一种原型人类血清(因其在整个细胞周期中与中心体具有强烈反应性而被选用)来筛选HeLa互补DNA(cDNA)(表达)文库。对阳性cDNA克隆进行测序,并分类为编码已知的中心体自身抗原、已知的中心体蛋白但未知为人类自身抗原的蛋白,或先前未知的中心体抗原。为研究这些中心体自身抗体类别是否为中心体反应性血清所特有,对21名通过间接免疫荧光检测具有中心体反应性的受试者的血清进行蛋白质印迹分析,以检测其对各类中心体抗原重组蛋白的反应性。通过回顾性病历审查研究临床特征。
在每一份血清中,均鉴定出了识别一组中心体蛋白的自身抗体。该组包括已知的中心体自身抗原(中心体周围蛋白和中心粒外周物质1 [PCM-1])、一种已知小鼠中心体蛋白的人类同源物ninein(其作为人类自身抗原此前未知),以及一种新的中心体蛋白(Cep250)。针对PCM-1的自身抗体最为少见(21名受试者中有8名;38%),而针对ninein、Cep250和中心体周围蛋白的自身抗体出现频率大致相同(分别为17名受试者 [81%]、17名受试者 [81%] 和19名受试者 [90%])。血清自身抗体反应性与临床诊断之间无明显相关性。
每一份自身免疫血清均含有与一组中心体蛋白发生反应的自身抗体。我们发现,首先在小鼠中鉴定出的中心体成分ninein具有作为自身抗原的人类同源物。此外,抗中心体血清含有针对先前未检测到的中心体成分的抗体。其中一种新抗原已被鉴定并命名为Cep250。因此,与中心体发生反应的血清的一个特征是它们含有针对一组中心体蛋白的抗体。